Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ghez

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Transfusion|September 21, 2007
Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresisFrançois Lefrère, Sarah Zohar, Sandrine Beaudier, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2021
Reduced frequency of cytotoxic CD56<sup>dim</sup> CD16<sup>+</sup> NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphomaElena Pánisová, Anna Lünemann, Simone Bürgler, et al.
Haematologica|April 6, 2006
A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphomaFrançois Lefrère, Sarah Zohar, Jean-Louis Bresson, et al.
American Journal of Hematology|November 23, 2017
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)Sophie Godet, Caroline Protin, Jehan Dupuis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2017
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphomaJulien Lazarovici, Marie Terroir, Julia Arfi-Rouche, et al.
Annals of Internal Medicine|October 16, 2002
Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapyLouis Bernard, Albert Vuagnat, Gilles Peytavin, et al.
Cancers|November 13, 2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 ImmunotherapyJean-Marie Michot, Severine Mouraud, Julien Adam, et al.
European Journal of Haematology|January 29, 2021
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapyPamela Abdayem, Nathalie Ibrahim, Yolla El Dakdouki, et al.
Cancer Medicine|April 7, 2020
Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomasKhalil Saleh, Jean-Marie Michot, Antoine Schernberg, et al.
Haematologica|February 16, 2023
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia <i>FLT3</i>-ITD patientsNicolas Vignal, Loïs Kelly, Etienne Lengline, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Transfusion|September 21, 2007
Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresisFrançois Lefrère, Sarah Zohar, Sandrine Beaudier, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2021
Reduced frequency of cytotoxic CD56<sup>dim</sup> CD16<sup>+</sup> NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphomaElena Pánisová, Anna Lünemann, Simone Bürgler, et al.
Haematologica|April 6, 2006
A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphomaFrançois Lefrère, Sarah Zohar, Jean-Louis Bresson, et al.
American Journal of Hematology|November 23, 2017
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)Sophie Godet, Caroline Protin, Jehan Dupuis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2017
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphomaJulien Lazarovici, Marie Terroir, Julia Arfi-Rouche, et al.
Annals of Internal Medicine|October 16, 2002
Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapyLouis Bernard, Albert Vuagnat, Gilles Peytavin, et al.
Cancers|November 13, 2021
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 ImmunotherapyJean-Marie Michot, Severine Mouraud, Julien Adam, et al.
European Journal of Haematology|January 29, 2021
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapyPamela Abdayem, Nathalie Ibrahim, Yolla El Dakdouki, et al.
Cancer Medicine|April 7, 2020
Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomasKhalil Saleh, Jean-Marie Michot, Antoine Schernberg, et al.
Haematologica|February 16, 2023
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia <i>FLT3</i>-ITD patientsNicolas Vignal, Loïs Kelly, Etienne Lengline, et al.
Pageof 8